secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2022-07-27T23:59:59+00:00
Accession:  0001104659-22-083183
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics CFO James O'Brien departs; Andrew Einhorn named interim CFO
--------------------------------------------------------------------------------

- CFO James O'Brien to leave effective August 12, 2022; departure not due to any disagreement with company or auditors.
- O'Brien eligible for severance: 9 months base salary and health benefits, contingent on release and restrictive covenants.
- Andrew Einhorn appointed Interim CFO effective August 12, via consulting agreement with Danforth Advisors.
- Einhorn previously CFO of RVL Pharmaceuticals and Edge Therapeutics; company will search for permanent CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465922083183/0001104659-22-083183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465922083183/tm2221873d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-083183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer